|
|
|
|
|
|
|
Highlights From The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
|
|
| Curing Early Bladder Cancer with Multidisciplinary Approaches
|
| Melissa Reimers, MD
|
| Melissa Reimers presented a discussant review of SAKK 06/19 and the AMBASSADOR HRQoL analysis, focusing on how multidisciplinary approaches may improve cure rates in early bladder cancer while preserving quality of life. Intravesical recombinant BCG may strengthen perioperative therapy and help support bladder-preservation strategies. Adjuvant pembrolizumab improved disease-free survival without meaningfully worsening overall HRQoL, though better biomarkers and patient-reported outcome tools are still needed.
|
|
|
|
|
|
| Enfortumab Vedotin + Pembrolizumab vs Chemotherapy for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 3.5 Year Follow-Up and Response Analyses from The Phase 3 EV-302 Study
|
| Thomas Powles, MBBS, MRCP, MD
|
| Thomas Powles presented 3.5-year follow-up from EV-302 showing that enfortumab vedotin plus pembrolizumab continues to deliver a durable overall survival and response benefit over chemotherapy in previously untreated advanced urothelial carcinoma. Responses often deepen over time, many complete responders convert from partial to complete response later, and long-term safety remains manageable with dose modifications.
|
|
|
|
|
|
| Initial Results from NEXUS-01, A Phase 1 Study of LY4052031, An ADC Targeting Nectin-4, In Participants with Advanced or Metastatic Urothelial Carcinoma
|
| Gopa Iyer, MD
|
| Gopa Iyer presented initial phase 1 results for LY4052031, a next-generation Nectin-4 ADC, in advanced or metastatic urothelial carcinoma. LY4052031 showed meaningful activity even after enfortumab vedotin, but CYP2D6 status strongly affected toxicity, making pharmacogenomic-guided dose optimization an important part of future development.
|
|
|
|
|
|
| HRQoL with Neoadjuvant and Adjuvant EV + Pembro in Patients with MIBC Who Are Cisplatin-Ineligible: Phase 3 KEYNOTE-905 Study
|
| Peter O'Donnell, MD
|
| Peter O'Donnel presented exploratory HRQoL results from KEYNOTE-905/EV-303 showing that perioperative enfortumab vedotin plus pembrolizumab preserved overall quality of life in cisplatin-ineligible patients with MIBC after cystectomy. Changes in general, cystectomy-specific, and overall health status did not reach clinically meaningful worsening, and bowel and sexual function declined in both arms largely because of the surgery itself rather than the added systemic therapy.
|
|
|
|
|
|
|
|
|
|
|
| Durvalumab Monotherapy Versus Active Monitoring for Resected Primary RCC in RAMPART: An International, Phase 3, Randomized Controlled Trial
|
| James Larkin, PhD, FRCP, FMedSci
|
| James Larkin presented results from the RAMPART trial showing that durvalumab plus tremelimumab improved disease-free survival after RCC surgery, while durvalumab alone did not clearly beat active monitoring. Benefit appeared concentrated in higher-risk patients and that toxicity was consistent with checkpoint blockade, including rare but serious immune-related deaths, without a clear quality-of-life difference at 15 months.
|
|
|
|
|
|
| Decision Regret and Toxicity Perception Following Adjuvant Immune Checkpoint Inhibitor in Renal Cell Carcinoma
|
| Elizabeth Nally
|
| Elizabeth Nally presented data showing that conventional HRQoL analyses may underestimate the long-term burden of adjuvant immune checkpoint inhibitor toxicity in RCC, because patients with serious side effects or recurrence are less likely to keep completing questionnaires. Patient-defined life-changing toxicity was linked to persistent quality-of-life impairment, and that decision regret was generally low but was highest in patients who experienced long-term toxicity.
|
|
|
|
|
|
| Feasibility and Safety Results from RAD-IO: A Multi-Stage Trial of Durvalumab with Chemoradiotherapy with 5-FU and Mitomycin C in Pts with MIBC
|
| Nicholas James, MBBS, PhD
|
| Professor Nick James presented feasibility and early efficacy results from RAD-IO, a bladder-preservation study testing durvalumab added to chemoradiotherapy with 5-FU and mitomycin C for MIBC. The regimen was feasible and tolerable, and the 12-month disease-free survival rate met the study’s prespecified go criterion, supporting further evaluation.
|
|
|
|
|
|
|
|
|
|
|
